Ergoteles’s Abeona Therapeutics ABEO Stock Holding History

Ergoteles’s Portfolio ABEO Stock Details ABEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-2,919	Closed	-$82K	–	1200
2021 Q3	$82K	Sell	2,919 -4,253	-59%	-$136K	﹤0.01%	1116
2021 Q2	$280K	Buy	+7,172	New	+$293K	0.01%	1106

Other funds holding ABEO

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Ergoteles's ABEO Position: Q4 2021 in Review

Ergoteles sold out of Abeona Therapeutics (ABEO) in Q4 2021, closing a stake of 2,919 shares — an estimated $82K sold.

Ergoteles first reported a position in ABEO in Q2 2021 and held it in 2 quarters. The position peaked at $280K in Q2 2021. 52 funds tracked by Wall St. Rank hold ABEO as of Q4 2021.

Ergoteles reported no remaining Abeona Therapeutics position as of Q4 2021 after selling out during the quarter.
Ergoteles sold 2,919 Abeona Therapeutics shares in Q4 2021, an estimated $82K.
Ergoteles first reported a position in Abeona Therapeutics in Q2 2021 and held it in 2 quarters.
Ergoteles's Abeona Therapeutics position peaked at $280K in Q2 2021.
52 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q4 2021.

Based on Ergoteles's 13F filing for Q4 2021, filed 14 Feb 2022.